

410.685 Emerging Issues in Biotechnology

Dr. Dave Gershon, MD, JD, MPH

Senior Healthcare Economics and Policy Advisor, Standard & Poor's
Adjunct Professor Healthcare Economics & Policy, Johns Hopkins University
Visiting Scholar Lecturer Healthcare Economics & Policy, McGill University
Visiting Professor Global Healthcare Policy & Social Entrepreneurship, University of Geneva

This course will focus on new global public-private partnerships in the biotechnology and pharmaceutical industry and the new business opportunities and new business models they create.

The drive towards better global health has been slowed by the emergence of virulent diseases such as HIV/AIDS, SARS, Malaria, Tuberculosis, and West Nile virus; rapidly changing microbial resistance to many drugs; and by an expanding global travel network that has shown the world how quickly a local disease in a developing country can transform into an international public health threat.

As part of this process global leaders are reevaluating the healthcare needs of their citizens and the advances in science that offer new opportunities for society. As a consequence, critical health legislation has been promulgated to redesign and restructure healthcare and social infrastructures. Emerging from this global effort are exciting new partnerships that engage the biotechnology and pharmaceutical industry, governments, and the non-profit sector in accelerating and advancing product development and the manufacturing of drugs, vaccines, and microbicides for pandemic diseases.

Over the past few years, in response to the demands from G8 leaders, the healthcare industry has been increasingly engaging in new global initiatives that are breaking through boundaries within government sectors, between government and non-governmental organizations and between the public and private sectors. Implicit in this engagement are new business opportunities and new business models that are coupled with heightened levels of global corporate social responsibility found in 'public-private' partnerships.

This course focuses on new global public-private partnerships as they have important implications for senior level decision makers in the biotechnology and pharmaceutical industries.

HIV VACCINE CLINICAL TRIALS AUGUST 2006



Grand Challenges in Global Health Bill Gates

<http://www.gcgh.org/>

International AIDS Vaccine Initiative

<http://www.iavi.org/>

One World Health

<http://www.oneworldhealth.org/diseases/malaria.php>

Biotech Monitor

<http://www.biotech-monitor.nl/4602.htm>

Time Magazine Conference World Health

<http://www.time.com/time/2005/globalhealth/programWed.html>

Novartis

<http://www.novartisfoundation.com/>

Bristol Myers-Squibb

<http://www.securethefuture.com/>

Glaxo Smith Kline

http://www.gsk.com/responsibility/cr_issues/dwc_accelerating_access.htm

Initiative on Public-Private Partnerships for Health

<http://www.ippph.org/>

National Institute for Pharmaco-Economics & Healthcare Policy
<http://www.healthcare-economics.org/team.htm>

World Health Organization
<http://www.who.int/trade/glossary/story077/en/index.html>

Science and Development Network
<http://www.scidev.net/dossiers/index.cfm?fuseaction=policybrief&dossier=6&policy=32>

Harvard
http://www.fas.harvard.edu/~acgei/Publications/Chen/LCC_PublicPrivate_Partnerships.pdf

US Department of State Building New Public-Private Partnerships
<http://www.state.gov/s/gac/rl/fs/2006/62974.htm>